ProLynx raises $70M for long-acting obesity treatments

ProLynx, a long-acting obesity and metabolic treatment biotech, has raised a $70 million Series A.

Why it matters: Weight-loss drugs have become one of the hottest areas in pharma, driving some of the year's biggest deals.